Edition:
United Kingdom

Nordic Nanovector ASA (NANOV.OL)

NANOV.OL on Oslo Stock Exchange

82.25NOK
19 Jan 2018
Change (% chg)

kr1.60 (+1.98%)
Prev Close
kr80.65
Open
kr80.65
Day's High
kr82.35
Day's Low
kr79.05
Volume
188,953
Avg. Vol
228,193
52-wk High
kr113.00
52-wk Low
kr66.40

Latest Key Developments (Source: Significant Developments)

Nordic Nanovector Q3 comprehensive loss widens to NOK 85.9 mln​
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - NORDIC NANOVECTOR ASA ::‍REVENUES FOR Q3 AMOUNTED TO NOK 0.1 MILLION (NOK 0.1 MILLION)​.‍TOTAL OPERATING EXPENSES FOR Q3 WERE NOK 72.7 MILLION (NOK 50.4 MILLION)​.‍COMPREHENSIVE LOSS FOR Q3 AMOUNTED TO NOK 85.9 MILLION (LOSS OF NOK 61.3 MILLION)​.  Full Article

Nordic Nanovector Q2 operating loss widens NOK 48.1 million
Wednesday, 24 Aug 2016 

Nordic Nanovector ASA : Q2 total operating revenue 0.1 million Norwegian crowns ($12,170) versus 0.1 million crowns year ago . Q2 operating loss 48.1 million crowns versus loss 51.1 million crowns year ago .Current cash resources are expected to be sufficient to reach first regulatory submission for Betalutin in FL in the first half of 2019.  Full Article

Nordic Nanovector and AREVA Med enter into collaboration
Tuesday, 28 Jun 2016 

Nordic Nanovector ASA : Says the company and AREVA Med to investigate potential of lead-212 conjugated anti-CD37 antibody for treating leukaemias . Will provide its chimeric anti-CD37 antibody (NNV003) and its expertise in antibody radionuclide conjugate (ARC) development . AREVA Med will provide expertise in production of 212pb . Preclinical studies will be conducted at AREVA Med's facility in Plano, Texas, USA .Has option to license any resulting ARCS for further development and AREVA med has option to license use of CD37-targeting antibodies for its own purposes.  Full Article

Nordic Nanovector Q1 operating loss widens to NOK 52.7 million
Thursday, 19 May 2016 

Nordic Nanovector ASA : Q1 revenue 0.078 million Norwegian crowns ($9,369.3) versus 0.076 million crowns year ago . Q1 operating loss 52.7 million crowns versus loss 35.8 million crowns year ago .Says current cash resources are expected to be sufficient to reach first regulatory submission for Betalutin in FL in H1 2019.  Full Article

Nordic Nanovector: Betalutin continues to show promising efficacy
Monday, 18 Apr 2016 

Nordic Nanovector ASA:Says Betalutin continues to show promising efficacy and increasing Duration of Response (DOR).Updated data confirm favourable safety profile of Betalutin.Says in Phase 1/2 study Betalutin was generally well tolerated and showed a 63.2 percent Overall Response Rate (ORR) including 31.6 percent Complete Response (CR) among 21 patients with previously treated CD37+ NHL patients.  Full Article

Nordic Nanovector ASA to cooperate with Paul Scherrer Institute to develop a leukaemia drug
Monday, 11 Apr 2016 

Nordic Nanovector ASA:Enters collaboration with Paul Scherrer Institute to develop new antibody radionuclide conjugates for treating leukaemias.Collaboration will benefit from grant funding from Research Council of Norway's user-driven research-based innovation program.  Full Article

Nordic Nanovector awarded NOK 15 million grant
Monday, 1 Feb 2016 

Nordic Nanovector ASA:Says has been awarded 15 million Norwegian crowns from the Research Council of Norway to research and develop novel targeted therapeutics.  Full Article

BRIEF-Oslo Bourse cuts REC, Nanovector from OBX, adds Norwegian Finans, Questerre

* OSLO BOURSE CUTS REC SILICON AND NORDIC NANOVECTOR FROM OBX INDEX, ADDS NORWEGIAN FINANS HOLDING AND QUESTERRE